IMS Health

Pharma Faces Longer Approval Times, Lower Reimbursement Rates in Years Ahead—Effective Payer KOLs the Answer

Pharmaceutical manufacturers will face longer regulatory approval times and lower reimbursement rates in the years ahead according to new IMS data. A recent IMS release summarizes market forecasting data, including reduced drug spending by public payers and more extensive reviews of new therapies. To navigate effectively through these new challenges, pharmaceutical companies will need a …

Pharma Faces Longer Approval Times, Lower Reimbursement Rates in Years Ahead—Effective Payer KOLs the Answer Read More »

US Prescription Sales Up in 2009; Top Therapy Areas Reflected in Thought Leader Select Projects

IMS Health reports a 5.1 percent increase in U.S. prescription sales in 2009. Demand for prescription drugs (new therapies and refills) as well as new treatment options for cancer, thrombosis and atrial fibrillation, and new generic treatment options drove growth in the year immediately preceding. Top therapy areas in 2009 include antipsychotics, lipid regulators, proton …

US Prescription Sales Up in 2009; Top Therapy Areas Reflected in Thought Leader Select Projects Read More »